Clinical trials: Dengue, open to volunteers
Healthy Volunteers, Dengue
Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection
Background: Dengue is a viral disease spread by mosquitoes. Most people bitten by mosquitoes carrying dengue viruses do not get sick, but severe cases can cause shock, internal bleeding, and death.
- Conditions
- Healthy Volunteers, Dengue, Human Challenge Trial
- Trial name
- NCT07706686
- Testing
- rDEN2delta30-7169
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)
The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are: 1.
- Trial name
- NCT07016321
- Testing
- Emetine Hydrochloride 6mg, Emetine Hydrochloride 12mg
- Where
- 2 sites in United States, Nepal
- Volunteers
- 600 people
- Sponsor
- Johns Hopkins University
Dengue, Antiviral Drugs
Adaptive Dengue Antiviral Platform Trial
This is a randomized, open-label adaptive platform trial aiming to screen the antiviral effectiveness of the experimental drug(s) in early dengue infection Primary objectives: To determine the antiviral effectiveness of the…
- Trial name
- ADAPT (NCT06551844)
- Testing
- Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg
- Where
- 2 sites in Malaysia, Vietnam
- Volunteers
- 500 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Dengue, Sepsis
Immune Responses to Dengue and Sepsis
The goal of this research study is to help the investigators better understand serious dengue disease. The investigators will collect clinical information and up to four blood samples from participants with dengue, influenza…
- Conditions
- Dengue, Sepsis, Influenza
- Trial name
- DEN-SEP (NCT07040202)
- Where
- 4 sites in Cambodia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Randomised Clinical Trial, Double Blind
Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults
This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study. Forty-two flavivirus-naïve adults will be enrolled and will receive 3 administrations of VLPDEN-02 or control at days 0, 28, and 56.
- Conditions
- Randomised Clinical Trial, Double Blind, Dengue, Challenge Test
- Trial name
- NCT07831473
- Testing
- VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- VLP Therapeutics
Dengue
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
- Trial name
- NCT06006559
- Testing
- EYU688
- Where
- 27 sites in Brazil, Colombia and 5 more
- Volunteers
- 108 people
- Sponsor
- Novartis Pharmaceuticals
Dengue Fever
Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)
The goal of this clinical trial is to understand if Resomelagon can treat adult patients with Dengue virus infection. The main questions the investigators aim to answer are: Is Resomelagon safe to use in patients with Dengue? Is…
- Trial name
- RESOVIR-2 (NCT06917001)
- Testing
- Resomelagon, Standard Treatment
- Where
- 2 sites in Brazil
- Volunteers
- 120 people
- Sponsor
- Federal University of Minas Gerais
Dengue
Investigating and Modelling the Natural History of Dengue in Hospitalised Patients to Improve Future Research
The goal of this observational study is to investigate the natural history of dengue in hospitalised patients in Vietnam, to better understand the disease process, and utilise the data to improve future clinical trials.
- Trial name
- DENEM (NCT07799168)
- Where
- Vietnam
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Emerging Infectious Diseases, COVID-19
Smart Analysis and Decision-Making for Emerging Infectious Diseases
Emerging infectious diseases, such as COVID-19, mpox, and dengue fever, are characterized by rapid transmission, wide impact, and high uncertainty, posing ongoing threats to global public health.
- Conditions
- Emerging Infectious Diseases, COVID-19, Influenza, Mpox (Monkeypox)
- Trial name
- SMART-ID (NCT07678619)
- Testing
- Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Peking University
Dengue, Dengue Hemorrhagic Fever
Gut Leakage' in Dengue
Dengue infections are imposing an increasing global burden of disease, particularly in tropical countries such as Bangladesh. The World Health Organization (WHO) has identified Dengue virus as a priority pathogen for the…
- Conditions
- Dengue, Dengue Hemorrhagic Fever, Intestinal Disease, Ascites
- Trial name
- GLiD (NCT07602920)
- Where
- Bangladesh
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Dengue Fever
Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)
ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in…
- Trial name
- ZAP-DENGUE (NCT04597437)
- Testing
- Zanamivir
- Where
- 2 sites in Colombia
- Volunteers
- 74 people
- Sponsor
- George Washington University
Dengue Fever With Warning Signs
Phase 3b Trial To Evaluate Safety And Immune Response (Superiority) of a Two-Dose Butantan-DV Regimen And The Standard Single Dose In Dengue-Naive Children/Adolescents and Immune Response (Non-inferiority) in a Manufacturing Facility Change (DEN-06-IB)
This randomized, double-blind, three parallel-group, multicenter, phase 3b trial evaluates the safety and immunogenicity of Butantan-DV. The study compares two primary immunization regimens (Butantan-DV/Butantan-DV vs.
- Trial name
- DEN-06-IB (NCT07712926)
- Testing
- Butantan-DV (IB), Butantan-DV (WuXi)
- Volunteers
- 1,765 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Dengue
Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)
This is a randomized, double-blind (60 -79 years) and open-label (40-59 years), three-arm parallel Phase 3b, multicenter study to evaluate the safety and non-inferiority of the humoral immune response of the Butantan Dengue…
- Trial name
- DEN-04-IB (NCT06891950)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 5 sites in Brazil
- Volunteers
- 997 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Dengue, Chikungunya
Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
This randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the…
- Trial name
- NCT06973772
- Testing
- DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555)
- Where
- 7 sites in Brazil
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Infectious Disease, Cardiovascular Diseases
Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study)
The aim of the present study is to determine the prevalence of cardiometabolic and infectious disease in La Reunion (french oversea department and region of France).
- Conditions
- Infectious Disease, Cardiovascular Diseases, General Population, Metabolic Disease
- Trial name
- NCT05400824
- Testing
- Blood, DNA, feces, urine, hair and skin microbiota collection
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Dengue
A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)
This is a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.
- Trial name
- NCT07576868
- Testing
- CP-COV03
- Where
- 2 sites in Vietnam
- Volunteers
- 210 people
- Sponsor
- Hyundai Bioscience Co., Ltd.
Dengue Fever
A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT06665035
- Testing
- TDV
- Where
- 4 sites in Colombia, Thailand
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- Takeda
Severe Dengue
Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)
The goal of this randomized double-blinded placebo-controlled trial is to learn about dexamethasone and the treatment of severe dengue population. The main question it aims to answer are steroid therapy may be effective in dengue.
- Trial name
- NCT05631405
- Testing
- Dexamethasone
- Where
- 2 sites in Thailand
- Volunteers
- 200 people
- Sponsor
- Chulalongkorn University
Dengue, Chikungunya
Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients
Introduction: Dengue and Chikungunya arboviral diseases are considered major public health challenges in tropical regions due to high infection rates and the occurrence of musculoskeletal sequelae that impair strength, balance…
- Trial name
- NCT07600879
- Testing
- Exercise
- Where
- Brazil
- Volunteers
- 54 people
- Sponsor
- Universidade do Estado do Pará
Dengue, Severe Dengue
Therapeutics for Moderate and Severe Dengue
The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection.
- Conditions
- Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases
- Trial name
- DEN-HOST (NCT07543458)
- Testing
- Dexamethasone, N-Acetylcysteine, Standard of care
- Where
- 18 sites in Bangladesh, Brazil and 8 more
- Volunteers
- 8,800 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam